Nefazodone Interactions

Strong CYP3A4 inhibitor causing significant increases in colchicine plasma levels.

Source: NLP:colchicine tablets 0.5 mg

Strong CYP3A4 inhibitor that increases simvastatin plasma levels, elevating risk of myopathy and rhabdomyolysis.

Source: NLP:ezetimibe and simvastatin

Strong CYP3A4 inhibitor may increase systemic corticosteroid effects of fluticasone propionate.

Source: NLP:fluticasone propionate

Strong CYP3A4 inhibitor may increase systemic corticosteroid and cardiovascular adverse effects when used with fluticasone propionate and salmeterol.

Source: NLP:fluticasone propionate and salmeterol

CYP3A4 inhibitor may increase systemic exposure to irinotecan or SN-38. Do not administer unless no therapeutic alternatives.

Source: NLP:irinotecan hydrochloride

Strong CYP3A4 inhibitor that increases ivabradine plasma concentrations, exacerbating bradycardia and conduction disturbances.

Source: NLP:ivabradine

Strong CYP3A4 inhibitor increases risk of myopathy by reducing lovastatin elimination.

Source: NLP:lovastatin

Strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vasospasm leading to cerebral ischemia and ischemia of extremities.

Source: NLP:methylergonovine maleate

Strong CYP3A inhibitor. Do not use with ranolazine extended-release tablets.

Source: NLP:ranolazine

Strong CYP3A4 inhibitor that increases simvastatin exposure and risk of myopathy and rhabdomyolysis. Concomitant use is contraindicated.

Source: NLP:simvastatin

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Source: NLP:suvorexant

Strong CYP3A inhibitor that substantially increases ticagrelor exposure, increasing risk of dyspnea, bleeding, and other adverse events.

Source: NLP:ticagrelor

Triazolam is contraindicated with nefazodone due to CYP 3A inhibition affecting triazolam metabolism.

Source: NLP:triazolam

Strong CYP3A4 inhibitor that may increase DM1 exposure and toxicity. Concomitant use should be avoided or KADCYLA treatment delayed.

Source: NLP:ado-trastuzumab emtansine

Strong CYP3A inhibitor may increase plasma concentrations of cabazitaxel. Avoid coadministration or consider 25% dose reduction.

Source: NLP:cabazitaxel

Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Source: NLP:erlotinib

Strong CYP3A4 inhibitor that increases erlotinib exposure and risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Source: NLP:erlotinib hydrochloride

Strong CYP3A4 inhibitor expected to increase eszopiclone exposure and effects similarly to ketoconazole. Dose reduction needed.

Source: NLP:eszopiclone

Strong CYP3A4 inhibitor may increase plasma concentration of triamcinolone leading to adverse reactions.

Source: NLP:lidocaine, kenalog, povidone iodine

CYP3A inhibitor that may increase nifedipine exposure. Careful monitoring and dose adjustment necessary; consider lowest dose.

Source: NLP:nifedipine

Strong CYP3A4 inhibitor that significantly increases nimodipine plasma concentration and blood pressure lowering effect. Concomitant administration should generally be avoided.

Source: NLP:nimodipine

Strong CYP3A inhibitor. Avoid concomitant use or reduce palbociclib dose if unavoidable.

Source: NLP:palbociclib

CYP3A4 inhibitor increases quetiapine exposure; dose reduction of quetiapine necessary.

Source: NLP:quetiapine

Potent CYP3A4 inhibitor that increases quetiapine exposure; dose adjustment necessary.

Source: NLP:quetiapine fumarate

Strong CYP3A4/5 inhibitor anticipated to significantly increase saxagliptin plasma concentrations. Dose limitation required.

Source: NLP:saxagliptin and metformin

May increase tacrolimus whole blood trough concentrations and increase risk of serious adverse reactions including neurotoxicity and QT prolongation. Reduce tacrolimus dose and adjust based on monitoring.

Source: NLP:tacrolimus

Strong CYP3A4 inhibitor may increase triamcinolone plasma concentration and adverse reactions.

Source: NLP:triamcinolone acetonide

Strong CYP3A4 inhibitor may increase systemic exposure to budesonide and cause systemic corticosteroid effects. Use with caution.

Source: NLP:albuterol sulfate and budesonide

Moderate CYP3A inhibitor may increase alprazolam concentrations; avoid use or consider dose reduction.

Source: NLP:alprazolam

Strong CYP3A4 inhibitor that may increase systemic exposure to budesonide. Use with caution.

Source: NLP:budesonide

Strong CYP3A4 inhibitor may increase systemic exposure to budesonide and increase systemic corticosteroid effects. Use with caution.

Source: NLP:budesonide and formoterol fumarate

Strong CYP3A4 inhibitor that may inhibit metabolism and increase systemic exposure to budesonide. Use with caution.

Source: NLP:budesonide inhalation

CYP3A4 inhibitor that may increase buspirone concentrations; concomitant use should be approached with caution.

Source: NLP:buspirone hydrochloride

CYP3A4 inhibitor may alter serum levels of calcifediol by inhibiting vitamin D metabolism enzymes. Dose adjustment and monitoring of serum 25-hydroxyvitamin D, PTH, and calcium may be required.

Source: NLP:calcifediol

CYP3A4 inhibitor that increases plasma levels of carbamazepine; dose adjustment and/or plasma level monitoring may be necessary.

Source: NLP:carbamazepine

Increases cyclosporine concentrations via CYP3A4 inhibition. Dosage adjustment essential.

Source: NLP:cyclosporine

Potent CYP3A4 inhibitor increases darifenacin systemic exposure. Daily dose should not exceed 7.5 mg when co-administered.

Source: NLP:darifenacin

Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.

Source: NLP:darifenacin hydrobromide

Increases digoxin serum concentration by 27% and AUC by 15%. Requires monitoring and dose adjustment.

Source: NLP:digoxin

Strong CYP 3A4 inhibitor; caution should be exercised when concomitantly administering with doxazosin mesylate.

Source: NLP:doxazosin mesylate

Significant CYP3A inhibitor; estazolam should be used with caution and appropriate dosage reduction may be needed.

Source: NLP:estazolam

Strong CYP3A4 inhibitor may increase systemic corticosteroid effects by inhibiting budesonide metabolism. Use with caution.

Source: NLP:budesonide and formoterol fumarate dihydrate

CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Source: NLP:haloperidol decanoate

CYP3A4 inhibitor that increases haloperidol plasma concentrations, raising risk of adverse events including QTc prolongation.

Source: NLP:haloperidol lactate

Strong CYP3A inhibitor may increase mifepristone plasma concentrations; limit mifepristone dose to 900 mg/day.

Source: NLP:mifepristone

Strong CYP3A inhibitor may increase mirtazapine plasma concentration. May require dose decrease.

Source: NLP:mirtazapine

Strong CYP3A4 inhibitor that may increase systemic corticosteroid effects of mometasone furoate. Use with caution and monitor for systemic corticosteroid side effects.

Source: NLP:mometasone furoate

Strong CYP3A4 inhibitor may increase systemic exposure to mometasone furoate and increase risk of systemic corticosteroid effects. Use with caution.

Source: NLP:mometasone furoate and formoterol fumarate dihydrate

CYP3A4 inhibitor; caution should be exercised when administering paclitaxel concomitantly.

Source: NLP:paclitaxel

Strong CYP3A inhibitor that increases paricalcitol exposure. Dose adjustment may be necessary; monitor iPTH and serum calcium.

Source: NLP:paricalcitol

Strong CYP3A4/5 inhibitor anticipated to significantly increase saxagliptin plasma concentrations. Saxagliptin dosage should be limited to 2.5 mg.

Source: NLP:saxagliptin